13 results for “Antibiogram”

Set a search alert

Research ArticleOpen accessIn the abstractSusceptibility and Detection of Extended Spectrum β-Lactamase Enzymes from Otitis Media PathogensEjikeugwu Chika, Iroha Ifeanyichukwu, Adikwu Michael, Esimone CharlesOtitis media is the bacterial infection of the middle ear usually accompanied with inflammation, effusions and pain. It can present clinically in two major forms: Acute Otitis Media (AOM) and Otitis Media with Effusion (OME) and it is one of the leading cause of hospital visits and antibiotic prescriptions amongst children and even adults. Antibiotic resistance is a global public … …American Journal of Infectious Diseases, Vol. 9, Issue 1 · 21 Mar 2013 · 7,970 accessesView PDF Cite

Research ArticleOpen accessIn the abstractStandard Versus Specific Therapy for Chronic Osteomyelitis TreatmentAngela Ingianni, Giorgio Lampis, Samuela Laconi et al.58 patients with chronic osteomyelitis were treated either with a standard therapy or with a specific targeted therapy based on the antibiogram assay. Standard therapy was performed by a 15-day course of a parenteral cephalosporin (usually ceftriaxone) in combination with an aminoglycoside (e.g. netilmicin), followed by oral therapy with a fluoroquinolone (generally ciprofloxacin) for 1 to 3 months; specific therapy … …American Journal of Infectious Diseases, Vol. 3, Issue 3 · 30 Sep 2007 · 6,874 accessesView PDF Cite

Research ArticleOpen accessIn the abstractPharmacodynamic Comparison of the Carbapenems Against E. coli and Klebsiella spp. Containing Extended spectrum β-lactamasesKathryn J. Eagye, Joseph L. Kuti, David P. NicolauCarbapenems are the treatment of choice for extended-spectrum β-lactamases (ESBLs). Ertapenem is a new member of the carbapenem class, and is often grouped with imipenem and meropenem as a recommended treatment for ESBLs. However, new in vitro data question ertapenem’s inclusion as a first line treatment for these bacteria, suggesting that ertapenem has a lower likelihood of obtaining appropriate pharmacodynamic … …American Journal of Infectious Diseases, Vol. 1, Issue 3 · 30 Sep 2005 · 6,886 accessesView PDF Cite